These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37576392)

  • 1. High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation.
    Wu Z; Zhuo T; Li Z; Zhu Y; Wu J; Liang G; Dai L; Wang Y; Tan X; Chen M
    J Cancer; 2023; 14(12):2301-2314. PubMed ID: 37576392
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
    He X; Ma Y; Huang Z; Wang G; Wang W; Zhang R; Guo G; Zhang X; Wen Y; Zhang L
    Thorac Cancer; 2023 Aug; 14(23):2275-2287. PubMed ID: 37424293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-Coding RNA-TMPO-AS1 as ceRNA Binding to let-7c-5p Upregulates STRIP2 Expression and Predicts Poor Prognosis in Lung Adenocarcinoma.
    Wang J; Yuan Y; Tang L; Zhai H; Zhang D; Duan L; Jiang X; Li C
    Front Oncol; 2022; 12():921200. PubMed ID: 35774125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments.
    Wang Z; Zhang M; Wu Y; Yu Y; Zheng Q; Li J
    J Cancer; 2021; 12(23):6964-6978. PubMed ID: 34729099
    [No Abstract]   [Full Text] [Related]  

  • 7. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INHA acts as a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment.
    Zhang X; Zhang X; Jiang D; Zheng W; Wang H; Tian Y; Cheng B
    Transl Oncol; 2023 Jul; 33():101679. PubMed ID: 37105130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
    Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
    Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
    Li L; Li J
    Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jiang F; Huang X; Yang X; Zhou H; Wang Y
    Front Oncol; 2022; 12():795971. PubMed ID: 35814368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
    Wei S; Xing J; Lu K; Wang K; Yu W
    Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.
    Hu HB; Yang XP; Zhou PX; Yang XA; Yin B
    Genes Genomics; 2020 Feb; 42(2):179-188. PubMed ID: 31768767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma.
    Cui Y; Wang X; Zhang L; Liu W; Ning J; Gu R; Cui Y; Cai L; Xing Y
    Front Oncol; 2022; 12():974614. PubMed ID: 36185284
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wang Y; Wen H; Sun D
    Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial-mesenchymal transition in lung adenocarcinoma.
    Dong Y; Zhang J; Xie S; Di S; Fan B; Gong T
    J Gene Med; 2024 Feb; 26(2):e3679. PubMed ID: 38404047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma.
    Tang S; Ni J; Chen B; Sun F; Huang J; Ni S; Tang Z
    BMC Cancer; 2022 May; 22(1):525. PubMed ID: 35534807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.
    Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L
    Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.